Charles Schwab Investment Management Inc. Has $3.88 Million Stock Position in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Charles Schwab Investment Management Inc. reduced its stake in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 14.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 210,211 shares of the company’s stock after selling 34,977 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.69% of Fulgent Genetics worth $3,883,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of FLGT. JPMorgan Chase & Co. raised its position in shares of Fulgent Genetics by 113.2% during the third quarter. JPMorgan Chase & Co. now owns 338,044 shares of the company’s stock valued at $7,346,000 after buying an additional 179,477 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Fulgent Genetics by 220.9% during the third quarter. BNP Paribas Financial Markets now owns 43,813 shares of the company’s stock valued at $952,000 after acquiring an additional 30,160 shares during the period. State Street Corp raised its holdings in Fulgent Genetics by 1.4% in the 3rd quarter. State Street Corp now owns 793,545 shares of the company’s stock valued at $17,244,000 after acquiring an additional 10,868 shares in the last quarter. Franklin Resources Inc. bought a new stake in shares of Fulgent Genetics in the 3rd quarter worth approximately $215,000. Finally, Geode Capital Management LLC grew its holdings in shares of Fulgent Genetics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 502,869 shares of the company’s stock worth $10,930,000 after purchasing an additional 13,320 shares in the last quarter. 48.06% of the stock is owned by institutional investors.

Insider Activity at Fulgent Genetics

In other news, CFO Paul Kim purchased 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was purchased at an average cost of $15.96 per share, with a total value of $1,596,000.00. Following the acquisition, the chief financial officer now directly owns 348,282 shares of the company’s stock, valued at approximately $5,558,580.72. This trade represents a 40.28 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 31.76% of the stock is owned by insiders.

Fulgent Genetics Trading Down 0.9 %

NASDAQ FLGT opened at $16.90 on Thursday. Fulgent Genetics, Inc. has a 1-year low of $14.57 and a 1-year high of $25.11. The company has a market capitalization of $521.01 million, a price-to-earnings ratio of -3.06 and a beta of 1.54. The stock’s 50 day moving average is $16.82 and its two-hundred day moving average is $18.73.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on FLGT shares. StockNews.com upgraded Fulgent Genetics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 5th. Piper Sandler dropped their price objective on shares of Fulgent Genetics from $22.00 to $16.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th.

Fulgent Genetics Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.